This recombinant monoclonal antibody is developed as a research-grade biosimilar to ixekizumab, targeting human interleukin-17A (IL17A), a proinflammatory cytokine central to immune-mediated diseases. IL17A is primarily produced by Th17 cells and plays a critical role in host defense against extracellular pathogens while also driving inflammatory responses. Dysregulated IL17A signaling has been implicated in the pathogenesis of autoimmune and inflammatory conditions, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and other spondyloarthropathies. By binding to IL17A, this antibody prevents its interaction with the IL17 receptor, thereby inhibiting downstream inflammatory cascades.
Ixekizumab is an FDA-approved humanized IgG4 monoclonal antibody widely used in clinical settings for treating moderate-to-severe plaque psoriasis and related inflammatory disorders. This biosimilar provides researchers with a valuable tool for investigating IL17A-mediated pathways, studying mechanisms of immune dysregulation, evaluating therapeutic interventions in preclinical models, and advancing understanding of cytokine biology in inflammatory disease contexts.
Email: support@cusabio.com
Distributors Worldwide